WEBINAR: Industrialization of the Manufacturing of a Gene Therapy Medicinal Product
Nicolas Preyat, Ph.D.
MaSTherCell, Belgium | Project and Development Manager
Recent advances in the field of gene editing technologies open new avenues for the implementation of cell and gene therapy therapeutic products. The development and manufacturing of disruptive Advanced Therapy Medicinal Products (ATMP) such as Chimeric Antigen Receptor (CAR) T cells is associated with a number of challenges. To ensure the success of the industrialization of CART from the bench to the bedside, there should be experts at each step of the process. Masthercell provides high quality services for the development and manufacturing of cell and gene therapy products in a cost and time efficient manner. Furthermore, to control the process of production and ensure the safety of the product, the complexity of the product should be characterized via appropriate analytical methods for which Masthercell can ensure the qualification/validation. MasTherCell also helps his customer through diagnostic services.
Learn more about Sartorius solutions for CAR-T Discovery & Development at www.sartorius.com/car-t-research.